OLMA / Olema Oncology to Participate in Upcoming Investor Conferences in November

SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage bioph more_horizontal

Olema Pharmaceuticals, Inc. (OLMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently more_horizontal

Olema Pharmaceuticals, Inc. (OLMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a prof more_horizontal

Olema Pharmaceuticals, Inc. (OLMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Ra more_horizontal

Olema Pharmaceuticals, Inc. (OLMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently more_horizontal

OLMA Overview: A clinical-stage biopharmaceutical company targeting ER+ breast cancer. The lead candidate, OP-1250, is a dual-function oral therapy pr more_horizontal

The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. more_horizontal

SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today tha more_horizontal